tetano
Editor, Senior Moderator
Cell Rep
. 2020 Jun 2;31(9):107725.
doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Huibin Lv[SUP] 1 [/SUP], Nicholas C Wu[SUP] 2 [/SUP], Owen Tak-Yin Tsang[SUP] 3 [/SUP], Meng Yuan[SUP] 2 [/SUP], Ranawaka A P M Perera[SUP] 4 [/SUP], Wai Shing Leung[SUP] 3 [/SUP], Ray T Y So[SUP] 1 [/SUP], Jacky Man Chun Chan[SUP] 3 [/SUP], Garrick K Yip[SUP] 1 [/SUP], Thomas Shiu Hong Chik[SUP] 3 [/SUP], Yiquan Wang[SUP] 1 [/SUP], Chris Yau Chung Choi[SUP] 3 [/SUP], Yihan Lin[SUP] 1 [/SUP], Wilson W Ng[SUP] 1 [/SUP], Jincun Zhao[SUP] 5 [/SUP], Leo L M Poon[SUP] 1 [/SUP], J S Malik Peiris[SUP] 6 [/SUP], Ian A Wilson[SUP] 7 [/SUP], Chris K P Mok[SUP] 8 [/SUP]
Affiliations
Abstract
The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
Copyright ? 2020 The Author(s). Published by Elsevier Inc. All rights reserved.
. 2020 Jun 2;31(9):107725.
doi: 10.1016/j.celrep.2020.107725. Epub 2020 May 18.
Cross-reactive Antibody Response between SARS-CoV-2 and SARS-CoV Infections
Huibin Lv[SUP] 1 [/SUP], Nicholas C Wu[SUP] 2 [/SUP], Owen Tak-Yin Tsang[SUP] 3 [/SUP], Meng Yuan[SUP] 2 [/SUP], Ranawaka A P M Perera[SUP] 4 [/SUP], Wai Shing Leung[SUP] 3 [/SUP], Ray T Y So[SUP] 1 [/SUP], Jacky Man Chun Chan[SUP] 3 [/SUP], Garrick K Yip[SUP] 1 [/SUP], Thomas Shiu Hong Chik[SUP] 3 [/SUP], Yiquan Wang[SUP] 1 [/SUP], Chris Yau Chung Choi[SUP] 3 [/SUP], Yihan Lin[SUP] 1 [/SUP], Wilson W Ng[SUP] 1 [/SUP], Jincun Zhao[SUP] 5 [/SUP], Leo L M Poon[SUP] 1 [/SUP], J S Malik Peiris[SUP] 6 [/SUP], Ian A Wilson[SUP] 7 [/SUP], Chris K P Mok[SUP] 8 [/SUP]
Affiliations
- PMID: 32684246
- DOI: 10.1016/j.celrep.2020.107725
Abstract
The World Health Organization has declared the ongoing outbreak of COVID-19, which is caused by a novel coronavirus SARS-CoV-2, a pandemic. There is currently a lack of knowledge about the antibody response elicited from SARS-CoV-2 infection. One major immunological question concerns antigenic differences between SARS-CoV-2 and SARS-CoV. We address this question by analyzing plasma from patients infected by SARS-CoV-2 or SARS-CoV and from infected or immunized mice. Our results show that, although cross-reactivity in antibody binding to the spike protein is common, cross-neutralization of the live viruses may be rare, indicating the presence of a non-neutralizing antibody response to conserved epitopes in the spike. Whether such low or non-neutralizing antibody response leads to antibody-dependent disease enhancement needs to be addressed in the future. Overall, this study not only addresses a fundamental question regarding antigenicity differences between SARS-CoV-2 and SARS-CoV but also has implications for immunogen design and vaccine development.
Copyright ? 2020 The Author(s). Published by Elsevier Inc. All rights reserved.